Anja Schneider

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2174738/publications.pdf

Version: 2024-02-01

61984 48315 9,023 152 43 citations h-index papers

g-index 170 170 170 12765 docs citations times ranked citing authors all docs

88

#	Article	IF	CITATIONS
1	Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica, 2002, 103, 26-35.	7.7	849
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
3	Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–Neuron Communication. PLoS Biology, 2013, 11, e1001604.	5.6	663
4	The release and trans-synaptic transmission of Tau via exosomes. Molecular Neurodegeneration, 2017, 12, 5.	10.8	475
5	Rapid Assembly of Alzheimer-like Paired Helical Filaments from Microtubule-Associated Protein Tau Monitored by Fluorescence in Solution. Biochemistry, 1998, 37, 10223-10230.	2.5	378
6	Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain, 2016, 139, 481-494.	7.6	349
7	Efficient Inhibition of the Alzheimer's Disease \hat{l}^2 -Secretase by Membrane Targeting. Science, 2008, 320, 520-523.	12.6	254
8	Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell and Tissue Research, 2013, 352, 33-47.	2.9	253
9	Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients. PLoS ONE, 2013, 8, e48814.	2.5	205
10	Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in Niemann-Pick Type C Disease. Journal of Biological Chemistry, 2010, 285, 26279-26288.	3.4	199
11	Upâ€regulation of the αâ€secretase ADAM10 by retinoic acid receptors and acitretin. FASEB Journal, 2009, 23, 1643-1654.	0.5	195
12	Flotillin-Dependent Clustering of the Amyloid Precursor Protein Regulates Its Endocytosis and Amyloidogenic Processing in Neurons. Journal of Neuroscience, 2008, 28, 2874-2882.	3.6	180
13	Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. Journal of Cell Biology, 2006, 172, 937-948.	5.2	151
14	Myelin Membrane Assembly Is Driven by a Phase Transition of Myelin Basic Proteins Into a Cohesive Protein Meshwork. PLoS Biology, 2013, 11, e1001577.	5.6	148
15	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
16	Extracellular vesicle sorting of \hat{l}_{\pm} -Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
17	Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. American Journal of Psychiatry, 2018, 175, 232-241.	7.2	133
18	Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 351-356.	1.7	131

#	Article	IF	CITATIONS
19	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
20	Tau-Based Treatment Strategies in Neurodegenerative Diseases. Neurotherapeutics, 2008, 5, 443-457.	4.4	128
21	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	3.1	125
22	LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587, 377-386.	27.8	108
23	Myelin basic protein-dependent plasma membrane reorganization in the formation of myelin. EMBO Journal, 2006, 25, 5037-5048.	7.8	99
24	Oligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain. Cell Metabolism, 2020, 32, 259-272.e10.	16.2	98
25	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
26	Polyâ€ <scp>GP</scp> in cerebrospinal fluid links <i>C9orf72</i> â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp> / <scp>FTD</scp> . EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
27	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
28	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
29	Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration. Journal of Neurochemistry, 2018, 147, 291-309.	3.9	84
30	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain, 2018, 141, 1186-1200.	7.6	83
31	Microtubule-Affinity Regulating Kinase (MARK) Is Tightly Associated with Neurofibrillary Tangles in Alzheimer Brain: A Fluorescence Resonance Energy Transfer Study. Journal of Neuropathology and Experimental Neurology, 2000, 59, 966-971.	1.7	82
32	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiology of Disease, 2006, 23, 573-577.	4.4	80
33	Neuron-to-neuron \hat{l}_{\pm} -synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathologica Communications, 2015, 3, 13.	5.2	75
34	The brain as immunoprecipitator of serum autoantibodies against Nâ€Methylâ€Dâ€aspartate receptor subunit NR1. Annals of Neurology, 2016, 79, 144-151.	5.3	75
35	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, $2019, 11, 66$.	6.2	74
36	A combined miRNA–piRNA signature to detect Alzheimer's disease. Translational Psychiatry, 2019, 9, 250.	4.8	74

#	Article	IF	Citations
37	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.1	73
38	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.1	72
39	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. Neurolmage: Clinical, 2017, 14, 656-662.	2.7	64
40	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. Journal of Neuroscience, 2019, 39, 8788-8797.	3.6	64
41	The diphenylpyrazole compound anle 138b blocks $\hat{Al^2}$ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	6.9	63
42	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
43	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
44	Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis. Journal of Biological Chemistry, 2004, 279, 55833-55839.	3.4	55
45	Choroid plexusâ€derived miRâ€204 regulates the number of quiescent neural stem cells in the adult brain. EMBO Journal, 2019, 38, e100481.	7.8	52
46	<scp>αâ€Synuclein</scp> in Plasmaâ€Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. Movement Disorders, 2021, 36, 2508-2518.	3.9	47
47	Palmitoylation is a sorting determinant for transport to the myelin membrane. Journal of Cell Science, 2005, 118, 2415-2423.	2.0	46
48	Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. Journal of Neuroscience, 2019, 39, 3752-3769.	3.6	46
49	Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 273-284.	3.2	44
50	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. Neurolmage: Clinical, 2017, 14, 334-343.	2.7	42
51	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
52	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
53	Turn Plasticity Distinguishes Different Modes of Amyloid- \hat{l}^2 Aggregation. Journal of the American Chemical Society, 2014, 136, 4913-4919.	13.7	39
54	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36

#	Article	IF	Citations
55	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging. Journal of Neurology, 2019, 266, 2465-2474.	3.6	35
56	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35
57	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	3.4	34
58	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
59	Prediction and Early Detection of Alzheimer's Dementia: Professional Disclosure Practices and Ethical Attitudes. Journal of Alzheimer's Disease, 2018, 62, 145-155.	2.6	29
60	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
61	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 2017, 7, 9529.	3.3	27
62	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
63	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
64	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.8	25
65	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
66	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
67	Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration. Science Advances, 2022, 8, .	10.3	22
68	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	2.4	21
69	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 191.	6.2	21
70	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	2.6	19
71	The atrophy pattern in Alzheimer-related PPA is more widespread than that of the frontotemporal lobar degeneration associated variants. Neurolmage: Clinical, 2019, 24, 101994.	2.7	18
72	Bupropion for the Treatment of Apathy in Alzheimer Disease. JAMA Network Open, 2020, 3, e206027.	5.9	18

#	Article	IF	CITATIONS
73	One-Stop Shop: ¹⁸ F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. Journal of Nuclear Medicine, 2021, 62, 240-246.	5.0	18
74	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 610-618.	2.4	17
75	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17
76	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkersâ€"results from the DELCODE study. Alzheimer's Research and Therapy, 2020, 12, 131.	6.2	17
77	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	2.7	17
78	Amyloid pathology but not <i> APOE </i> $\hat{l}\mu 4$ status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	7.6	17
79	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. Brain, 2022, 145, 2507-2517.	7.6	16
80	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	2.6	15
81	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
82	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. NeuroImage: Clinical, 2021, 29, 102533.	2.7	15
83	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974.	3.4	15
84	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	2.6	14
85	MicroRNAs from extracellular vesicles as a signature for Parkinson's disease. Clinical and Translational Medicine, 2021, 11, e357.	4.0	14
86	Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool forÂAlzheimer's Disease Diagnostics. Journal of Alzheimer's Disease, 2015, 46, 1007-1020.	2.6	12
87	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	2.9	12
88	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	2.6	12
89	Feasibility of Digital Memory Assessments in an Unsupervised and Remote Study Setting. Frontiers in Digital Health, 0, 4, .	2.8	12
90	Network Localization of Alien Limb in Patients with Corticobasal Syndrome. Annals of Neurology, 2020, 88, 1118-1131.	5.3	11

#	Article	IF	Citations
91	Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	2.7	10
92	Glucocorticoid Therapy is Associated with a Lower Risk of Dementia. Journal of Alzheimer's Disease, 2020, 73, 175-183.	2.6	10
93	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10
94	Catching filopodia: Exosomes surf on fast highways to enter cells. Journal of Cell Biology, 2016, 213, 143-145.	5.2	9
95	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
96	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. Acta Neuropathologica, 2014, 128, 893-5.	7.7	8
97	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
98	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	8
99	The impact of COVID-19-related distress on levels of depression, anxiety and quality of life in psychogeriatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 53-66.	3.2	8
100	Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. Journal of Alzheimer's Disease, 2020, 78, 1137-1148.	2.6	5
101	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5
102	A rare heterozygous <i>TREM2</i> coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181.	2.5	4
103	A Novel Mutation of the Arylsulfatase A Gene in Late-Onset Metachromatic Leukodystrophy. Journal of Clinical Psychiatry, 2009, 70, 1724-1725.	2.2	4
104	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	2.4	4
105	Antioxidative strategies in cognitive impairment: a novel connection between biliverdinâ€reductase and statins. Journal of Neurochemistry, 2012, 120, 1-3.	3.9	3
106	Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 973-984.	3.2	3
107	[ICâ€Pâ€080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARK FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P66.	ER 0.8	2
108	[P3–437]: LATENTâ€FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. Alzheimer's and Dementia, 2017, 13, P1136.	0.8	2

#	Article	IF	Citations
109	[P1–122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.8	2
110	[P2â€"390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.8	1
111	P4â€068: LEVELS OF THE ASTROCYTEâ€DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458.	0.8	1
112	Feasibility of mobile appâ€based assessment of memory functions: Insights from a citizen science study. Alzheimer's and Dementia, 2020, 16, e039149.	0.8	1
113	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.8	1
114	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. Alzheimer's and Dementia, 2021, 17, .	0.8	1
115	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	1
116	P1-010: Face Name Associative Recognition is Associated with Alzheimer's Disease Biomarkers in Patients with Subjective Cognitive Decline. , 2016, 12, P402-P403.		0
117	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.8	О
118	[P2–074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.8	0
119	[P3–393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER's DISEASE BASED ON MULTICENTER RESTINGâ€STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1112.	0.8	O
120	[P4–248]: QUALITY ASSURANCE IN DELCODE: A MULTIâ€CENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.8	0
121	[P4–532]: OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER's DISEASE AND MRI VOLUMETRY. Alzheimer's and Dementia, 2017, 13, P1553.	0.8	O
122	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.8	0
123	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.8	O
124	P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879.	0.8	0
125	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.8	O
126	ICâ€Pâ€084: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P72.	0.8	0

#	Article	IF	CITATIONS
127	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.8	O
128	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES O ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	F 0.8	0
129	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.8	O
130	F4â€07â€03: RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1393.	IN 0.8	0
131	ICâ€Pâ€163: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P137.	0.8	О
132	F1â€04â€02: ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER'S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY. Alzheimer's and Dementia, 2018, 14, P206.	0.8	0
133	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.8	O
134	F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207.	0.8	0
135	P2â€431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, βâ€AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.8	O
136	P2â€447: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P888.	0.8	0
137	ICâ€Pâ€028: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. Alzheimer's and Dementia, 2019, 15, P35.	0.8	О
138	ICâ€Pâ€016: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLI BASALIS MEYNERT IN AMYLOIDâ€POSITIVE SCD. Alzheimer's and Dementia, 2019, 15, P25.	EUS 0.8	0
139	Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study. Alzheimer's and Dementia, 2020, 16, e040265.	0.8	O
140	Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study. Alzheimer's and Dementia, 2020, 16, e040416.	0.8	0
141	Lifestyle differences modulate the effects of cognitive reserve on functional connectivity. Alzheimer's and Dementia, 2020, 16, e042947.	0.8	O
142	Hippocampal volumetric variability is associated with memory in subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e043527.	0.8	0
143	Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744.	0.8	O
144	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349.	0.8	0

#	Article	IF	CITATIONS
145	Performance comparison of automated white matter lesion segmentation algorithms in the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e045367.	0.8	O
146	Association of domainâ€specific cognitive functions with regional pattern of atrophy and functional connectivity across the Alzheimer's disease spectrum: An analysis from the DELCODE cohort. Alzheimer's and Dementia, 2020, 16, e042992.	0.8	0
147	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
148	Cost of illness of apathy in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
149	Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
150	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, $2021,17,$.	0.8	0
151	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, .	0.8	0
152	Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, .	0.8	0